Learn how one of the world’s leading pharmaceutical companies propelled the prevalence rate among newly diagnosed COPD patients to 7.7% with DeepIntent’s Patient Modeled Audiences.
Learn how one of the world’s leading pharmaceutical companies propelled the prevalence rate among newly diagnosed COPD patients to 7.7% with DeepIntent’s Patient Modeled Audiences.